Gilead Sciences Inc. (GILD)
GILD · Health Care · 
United States
Gilead Sciences Inc. (GILD) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 3.07%. Anyone who holds an ETF containing Gilead Sciences also has an indirect stake in the company.
Data and Charts: Gilead Sciences
Key Data for Gilead Sciences
Gilead Sciences Stock Price Chart
The Gilead Sciences chart shows daily closing prices and is set to the current year by default. The stock is up 39.1% year to date and up 44.1% over twelve months. The last recorded close on October 30, 2026, was $170.68, at 100% of the 52-week range.
Price series from our database since Jul 11, 2024, 580 daily values.
Gilead Sciences Stock Performance
| Year to date | +39.1% | 1 year | +44.1% |
|---|---|---|---|
| 1 month | +14.5% | 3 months | +31.1% |
| Calendar year 2025 | +32.9% |
Measured in euros, Gilead Sciences is up 46.3% year to date and up 49.0% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Gilead Sciences
Gilead Sciences Connections
The map shows how Gilead Sciences connects to ETFs, indices and other names. Each link is based on measured data and is not a recommendation.
- MSCI USA Health Care Index · contains
- United States Country · domicile
- XUHL ETF · holds
- XUHC ETF · holds
- XDWH ETF · holds
- SPFS ETF · holds
- Health Care Sector · sector
- Amgen Stock · similar ETF exposure
- GE Healthcare Technologies Stock · similar ETF exposure
- IDEXX Laboratories Stock · similar ETF exposure
- Vertex Pharmaceuticals Incorporated Stock · similar ETF exposure
What ETF Is Gilead Sciences In?
Gilead Sciences has very high ETF coverage and is held by 27 of the 104 ETFs we track, which together follow 14 indices. That puts the stock in more ETFs than 95.5% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 3.07% | €30.66 |
| SPFS | MSCI World Health Care | 2.28% | €22.81 |
| XDWH | MSCI World Health Care | 2.27% | €22.67 |
| 2B7K | MSCI World SRI | 0.94% | €9.40 |
| EXXT | Nasdaq 100 | 0.89% | €8.90 |
| XNAS / XNA1 | Nasdaq 100 | 0.89% | €8.90 |
| XDEV | MSCI World Value | 0.52% | €5.24 |
| XDEQ | MSCI World Quality | 0.51% | €5.09 |
| XDEB | MSCI World Minimum Volatility | 0.41% | €4.12 |
| SPYL / SPY5 | S&P 500 | 0.31% | €3.10 |
| SXR8 | S&P 500 | 0.31% | €3.10 |
| XD9U / XD9D | MSCI USA | 0.31% | €3.08 |
| EUNL | MSCI World | 0.23% | €2.30 |
| XDWD / XDWL | MSCI World | 0.23% | €2.25 |
| SWWD | MSCI World | 0.22% | €2.25 |
| SPPW | MSCI World | 0.22% | €2.25 |
| XDEW | S&P 500 Equal Weight | 0.22% | €2.21 |
| SPYI / SPSA | MSCI ACWI IMI | 0.21% | €2.12 |
| SPYY | MSCI ACWI | 0.20% | €2.03 |
| WIMI | MSCI World IMI | 0.20% | €2.02 |
| IUSQ | MSCI ACWI | 0.20% | €2.00 |
The last column shows how much of €1,000 in one of these funds goes to Gilead Sciences, based on each fund's latest holdings list.
US-listed ETFs holding Gilead Sciences (weight per latest SEC filing): QQQM 0.80%, QQQ 0.68%, VYM 0.66%, ONEQ 0.39%, IVV 0.24%, SPY 0.24%, VOO 0.24%, VTI 0.22%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Gilead Sciences Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Gilead Sciences had a weight of 0.20% on Sep 30, 2019 and 0.23% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.27% on Mar 31, 2020. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Gilead Sciences overlaps with the rest of a portfolio.
Which Tracked Investors Hold Gilead Sciences?
Gilead Sciences is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds Gilead Sciences increased its position.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 290,881 | $37M | increased by 110,144 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
What Gilead Sciences Executives and Directors Traded Recently
| Date | Person | Type | Shares | Price |
|---|---|---|---|---|
| Oct 15, 2026 | Mercier Johanna Officer, Chief Comm & Corp Aff Officer | Sell (plan) | 3,000 | $156.22 |
| Oct 15, 2026 | Dickinson Andrew D Officer, Chief Financial Officer | Sell (plan) | 3,000 | $156.22 |
| Oct 1, 2026 | O'Day Daniel Patrick Director, Officer, Chairman & CEO | Sell (plan) | 3,000 | $148.63 |
| Oct 1, 2026 | O'Day Daniel Patrick Director, Officer, Chairman & CEO | Sell (plan) | 12,000 | $147.72 |
The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded.
“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32.
Stocks With ETF Exposure Similar to Gilead Sciences
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Gilead Sciences | – | – | +44.1% | 26.8% | 28.9% | +2.4% |
 Vertex Pharmaceuticals Incorporated | 26 | – | +33.1% | 31.8% | 32.9% | +8.9% |
 IDEXX Laboratories | 25 | – | -12.3% | 36.6% | 24.6% | +10.4% |
 Amgen | 25 | +0.58 | +59.6% | 27.7% | 21.0% | +10.0% |
 Regeneron Pharmaceuticals | 24 | – | +41.9% | 36.5% | 31.4% | +1.0% |
 DexCom | 24 | – | +20.7% | 40.8% | 17.9% | +15.6% |
 GE Healthcare Technologies | 24 | – | +2.1% | 34.1% | 10.1% | +4.8% |
 Incyte Corporation | 23 | +0.59 | +30.0% | 34.0% | 25.0% | +21.2% |
 Intuitive Surgical | 23 | – | -18.5% | 34.2% | 28.4% | +20.5% |
These stocks reach a portfolio through largely the same funds as Gilead Sciences. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Gilead Sciences
Gilead Sciences Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 27.1 | 5.7 | 20.9% |
| FY ended Dec 2024 | 28.8 | 0.5 | 1.7% |
| FY ended Dec 2025 | 29.4 | 8.5 | 28.9% |
Technical Analysis: Gilead Sciences
Gilead Sciences Risk Metrics
The close on Oct 30, 2026, was the highest since our series began on Jul 11, 2024. When the S&P 500 rose or fell 1%, Gilead Sciences moved 0.26% on average in the same direction (past 252 trading days). The correlation of 0.12, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Gilead Sciences.
What Gilead Sciences Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Royalty Pharma Plc Class A | +0.64 | |
| Pfizer Inc. | +0.62 | |
| Bristol-Myers Squibb Company | +0.60 | |
| Incyte Corporation | +0.59 | |
| Amgen Inc. | +0.58 | |
| AbbVie Inc. | +0.56 | |
| YB | -0.46 | |
| PYR | -0.46 | |
| Teradyne Inc. | -0.45 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
